Edwards Lifesciences (EW) Deferred Taxes (2009 - 2026)

Edwards Lifesciences has reported Deferred Taxes for 18 years, with the latest figure at -$181.3 million in Q2 2026.

• On a quarterly basis, Deferred Taxes fell 967.46% year-over-year to -$181.3 million in Q2 2026; TTM through Jun 2026 was -$118.3 million, a 144.36% decrease from a year earlier, with the FY2025 full-year figure at $117.6 million, down 63.64% from the prior year.
• Deferred Taxes was -$181.3 million for Q2 2026 at Edwards Lifesciences, down from -$9.4 million in the prior quarter.
• The five-year high for Deferred Taxes was $123.0 million in Q3 2024, with the low at -$181.3 million in Q2 2026.
• Average Deferred Taxes over 5 years is $43.2 million, with a median of $49.0 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Deferred Taxes jumped 1287.18% in 2022, then tumbled 967.46% in 2026.
• Over 5 years, Deferred Taxes stood at $105.8 million in 2022, then retreated by 13.61% to $91.4 million in 2023, then grew by 7.77% to $98.5 million in 2024, then slumped by 44.77% to $54.4 million in 2025, then tumbled by 433.27% to -$181.3 million in 2026.
• The last three Deferred Taxes figures came in at -$181.3 million (Q2 2026), -$9.4 million (Q1 2026), and $54.4 million (Q4 2025), per Business Quant data.